Targeting of CD73 offers potential in this context [17–19]; as CD73 protein expression may be increased in treatment-resistant cancer cells and host-derived cells such as immunosuppressive Tregs in the tumor microenvironment, CD73 blockade may result in immune stimulation and antitumor activity [4, 10]. The gene discussed is NT5E; the disease is cancer.